Showing results (51-60 of 66) with videos related to
Sort By:
Pageof 7
Acta Neuropathologica|June 11, 2020
Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resourceKyle S Smith, Ke Xu, Kimberly S Mercer, et al.JAMA Oncology|July 22, 2021
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology GroupSarah E S Leary, Roger J Packer, Yimei Li, et al.Neuro-Oncology|October 29, 2025
An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survivalAuthors Kyle S Smith, Sandeep K Dhanda, Catherine A Billups, et al.Nature Communications|December 22, 2019
scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapyJennifer Karin Ocasio, Benjamin Babcock, Daniel Malawsky, et al.Genes & Development|August 22, 2020
Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formationLena M Kutscher, Konstantin Okonechnikov, Nadja V Batora, et al.Nature|September 21, 2022
Unified rhombic lip origins of group 3 and group 4 medulloblastomaKyle S Smith, Laure Bihannic, Brian L Gudenas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJeff M Michalski, Anna J Janss, L Gilbert Vezina, et al.Nature Cancer|February 17, 2026
M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumorsKyle S Smith, Tom T Fischer, Katie Han, et al.Cancer Cell|October 22, 2021
Serial assessment of measurable residual disease in medulloblastoma liquid biopsiesAnthony P Y Liu, Kyle S Smith, Rahul Kumar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)Amar Gajjar, Giles W Robinson, Kyle S Smith, et al.Pageof 7